Drug Profile

Research programme: alpha targeted cancer therapeutics - Alpha Fusion/Mitsubishi Tanabe Pharma Corporation/Veneno Technologies

Latest Information Update: 17 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Mitsubishi Tanabe Pharma Corporation
Developer Alpha Fusion; Mitsubishi Tanabe Pharma Corporation
Class Antineoplastics; Peptide drug conjugates; Peptides; Radioisotopes; Radiopharmaceuticals
Mechanism of Action Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

03 Oct 2025 Early research in Cancer in Japan prior to July 2025 (Parenteral)
10 Jul 2025 Mitsubishi Tanabe Pharma Corporation initiates joint research in Japan with Veneno Technologies and Alpha Fusion on the development of Targeted Alpha Therapy

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com